RPL36AP51

Across TCGA pan-cancer cohorts, RPL36AP51 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RPL36AP51 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPL36AP51 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL36AP51 expression acts as an unfavorable survival marker.

OV are the cancer types where RPL36AP51 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.346	0.843	.003	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RPL36AP51–OV (OS)

Open the OV breakdown →